banner

News Releases

Date Title and Summary  
Toggle Summary ACADIA Announces Chemical-Genomics Collaboration with Amgen to Discover Small Molecule Drugs
SAN DIEGO, CA, January 3, 2002 - ACADIA Pharmaceuticals announced today that it has established a collaboration with Amgen (Nasdaq: AMGN) to discover novel small molecule drugs using ACADIA's proprietary chemical-genomics platform. The companies will apply ACADIA's discovery platform to identify
Printer Friendly Version
Toggle Summary ACADIA Applies Chemical Genomics to Discover Small Molecule Leads for Numerous GPCRs and Nuclear Rececptors
Proprietary platform has identified novel chemistries for over 60 targets including the first agonists for HNF4 a and PAR2 SAN DIEGO, CA, June 13, 2002 – ACADIA Pharmaceuticals announced the successful application of its proprietary chemical-genomics approach to more than 100 G-protein coupled
Printer Friendly Version
Toggle Summary ACADIA Discovers Novel Small Molecule Leads for the V2 Vasopressin Receptor
Chemical-Genomics Platform Enables Discovery Of Small Molecule Activators Of Numerous Peptide GPCRs SAN DIEGO, CA and COPENHAGEN, DK, September 26, 2002 - ACADIA Pharmaceuticals announced today the discovery of small molecule lead chemistries for the V2 Vasopressin receptor.
Printer Friendly Version
Toggle Summary Paul S. Anderson, Ph.D., Appointed To ACADIA Pharmaceutical's Scientific Advisory Board
SAN DIEGO, CA and COPENHAGEN, DK, November 13, 2002 - ACADIA Pharmaceuticals announced today the appointment of Paul S. Anderson, Ph.D., to its Scientific Advisory Board. Dr. Anderson is one of the world's most highly respected medical chemists and has nearly 40 years of experience in drug
Printer Friendly Version
Toggle Summary ACADIA Expands Pain Portfolio to Include New GPCR Targets
Discovery of First Small Molecule Agonists for NPFF and MrG Receptors SAN DIEGO, CA, December 10, 2002 - ACADIA Pharmaceuticals announced today the discovery of the first small molecule chemistries that activate two important G-protein coupled receptor (GPCR) targets, the NPFF and the MrG
Printer Friendly Version
Toggle Summary ACADIA Initiates Clinical Trials for ACP-103 - Initially Targets Treatment-Induced Dysfunction in Parkinson's Disease
SAN DIEGO, CA and COPENHAGEN, DK, January 22, 2003 - ACADIA Pharmaceuticals announced today that it has initiated Phase I clinical trials for ACP-103, a small molecule drug candidate that represents an important new approach to amelioration of treatment-induced dysfunction in Parkinson's disease as
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Completes $25 Million Private Placement
Alan G. Walton of Oxford Bioscience Partners Appointed to ACADIA's Board of Directors SAN DIEGO, CA, and COPENHAGEN, DK, March 28, 2003 - ACADIA Pharmaceuticals announced today that it has completed a $25 million private placement of its preferred stock.
Printer Friendly Version
Toggle Summary Allergan and ACADIA Pharmaceuticals Announce New Drug Discovery and Development Collaboration
Collaboration to Pursue Numerous Target-Specific Chemistries in Eye Care and Other Indications SAN DIEGO, CA, April 15, 2003 - ACADIA Pharmaceuticals announced today it has established a new drug discovery and development collaboration with Allergan, Inc. (NYSE: AGN).
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Expands Private Placement to $28 Million
Gordon Binder of Coastview Capital Appointed to ACADIA's Board of Directors SAN DIEGO, CA, and COPENHAGEN, DK, June 12, 2003 – ACADIA Pharmaceuticals announced today that it has completed a follow-on closing of its private placement to include a new equity investment by funds managed by Coastview
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Successfully Completes Phase I Clinical Testing of ACP-103
Proprietary Small Molecule 5-HT2A Inverse Agonist Appears Safe and Well Tolerated SAN DIEGO, CA, and COPENHAGEN, DK, August 6, 2003 – ACADIA Pharmaceuticals announced today that it has successfully completed Phase I clinical testing of ACP-103, the Company's proprietary small molecule 5-HT2A
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Achieves Milestone as Allergan Advances Glaucoma Drug Candidate
Selective Muscarinic Compounds Demonstrate Promising Preclinical Profile SAN DIEGO, CA and COPENHAGEN, DENMARK, January 8, 2004 - ACADIA Pharmaceuticals announced today that it has achieved a milestone in its collaboration agreement with Allergan (NYSE: AGN) to discover, develop, and commercialize
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Initial Public Offering
SAN DIEGO, May 26 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a price of $7.00 per share. All of the shares are being offered by ACADIA.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Presents Favorable Results From Phase Ib/IIa Clinical Trial and PET Study of ACP-103
PHILADELPHIA, June 29 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) presented, at the CNS Diseases Congress held in Philadelphia, results of a Phase Ib/IIa clinical trial of ACP-103 in patients with Parkinson's disease and results from a human brain receptor occupancy study
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 24th Annual Adams Harkness Summer Seminar on August 5, 2004
SAN DIEGO, Jul 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it will present at the 24th Annual Adams Harkness Summer Seminar on Thursday, August 5, 2004, at 4:00 pm EDT. ACADIA's presentation will be given by Uli Hacksell, Ph.D.,
Printer Friendly Version
Toggle Summary ACADIA Study Links ACP-104 (N-desmethylclozapine) to Improved Cognition in Schizophrenia Patients
ACADIA's Clinical Development of ACP-104 Supported by The Stanley Medical Research Institute SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Inc. Second Quarter 2004 Earnings Conference Call
SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2004--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report second quarter
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2004 Financial Results on August 11, 2004
Will Host Conference Call and Webcast on Wednesday, August 11, 2004 at 4:30 p.m. EDT SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel treatments
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2004 Financial Results
SAN DIEGO, Aug 11, 2004 /PRNewswire via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported financial results for the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Expand Scandinavian Chemistry Operations
SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Medeon Science Park today announced plans to establish a modern chemistry research and development facility in Malmo, Sweden. The new laboratory, under construction by Medeon Fastigheter AB, is centrally
Printer Friendly Version
Toggle Summary ACADIA Clinical Study Shows ACP-103 Improves Clinical Profile of Antipsychotic Drug Treatment
SAN DIEGO, Sep 15, 2004 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported results from a
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Bio Emerging Company Investor Forum
SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that it will present at the Bio Emerging Company Investor Forum on Wednesday, October 13, at 2:20 pm PDT. ACADIA's presentation will be given by Uli Hacksell, Ph.D., its Chief Executive Officer,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on October 26, 2004
SAN DIEGO, Oct 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on October 26, 2004, at 3:50 pm Eastern Time at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Earns Milestone on Advancement of Neuropathic Pain Drug
SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Allergan, Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2004 Financial Results on November 10, 2004
Will Host Conference Call and Webcast on Wednesday, November 10, 2004 at 4:30 p.m. EST SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Inc. Third Quarter 2004 Earnings Conference Call
SAN DIEGO--(BUSINESS WIRE)--Nov. 4, 2004--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report third
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2004 Financial Results
SAN DIEGO, Nov 10, 2004 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Partnership With Sepracor
SAN DIEGO, Jan 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Piper Jaffray 17th Annual Health Care Conference on January 26, 2005
SAN DIEGO, Jan. 19 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the Piper Jaffray 17th Annual Health Care Conference on January 26, 2005, at 3:30 pm Eastern Time at The Pierre Hotel in New
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 24, 2005
SAN DIEGO, Feb 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the BIO CEO & Investor Conference on Thursday, February 24, 2005, at 2:30 pm Eastern Time at the Waldorf=Astoria
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, Feb 22, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the following upcoming investor conferences: * The Wells Fargo Securities HealthCare Conference on Tuesday,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2004 Financial Results on March 3, 2005
ACADIA to Host Conference Call and Webcast on Thursday, March 3, 2005 at 4:30 p.m. Eastern Time SAN DIEGO, Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2004
SAN DIEGO, March 3, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its
Printer Friendly Version
Toggle Summary ACADIA Announces Management Appointments in Business Development and Research and Development
SAN DIEGO, March 7, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Future Leaders in the Biotech Industry Conference on April 7, 2005
SAN DIEGO, March 31, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the Future Leaders in the Biotech Industry Conference on Thursday, April 7, 2005, at 9:30 a.m.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces $36 Million Financing
SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Election of Mary Ann Gray, Ph.D. to Board of Directors
SAN DIEGO, April 28, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2005 Financial Results on May 11, 2005
ACADIA to Host Conference Call and Webcast on Wednesday, May 11, 2005 at 4:30 p.m. Eastern Time SAN DIEGO, May 4, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Banc of America Securities Health Care Conference 2005
SAN DIEGO, May 10, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the Banc of America Securities Health Care Conference 2005 on Tuesday, May 17, at 12:00 p.m.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2005 Financial Results
SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Expands Technology Platform to Target Tyrosine Kinase Linked Receptors
Novel Assay Technologies Highlighted at Molecular Pharmacology Gordon Conference and ASCO Annual Meeting 2005 SAN DIEGO, May 17, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Fourth Annual Needham Biotechnology Conference
SAN DIEGO, May 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the Fourth Annual Needham Biotechnology Conference on Thursday, May 26, 2005, at 3:30 p.m.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Encouraging Interim Results From Ongoing Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease
SAN DIEGO, June 22 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, today reported encouraging results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 25th Annual Adams Harkness Summer Seminar on August 3, 2005
SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the 25th Annual Adams Harkness Summer Seminar on Wednesday, August 3, 2005, at 11:00 a.m.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2005 Financial Results on August 10, 2005
ACADIA to Host Conference Call and Webcast on Wednesday, August 10, 2005 at 4:30 p.m. Eastern Time SAN DIEGO, Aug. 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2005 Financial Results
SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 8th Annual San Diego Growth Conference on August 19, 2005
SAN DIEGO, Aug. 17 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the 8th Annual San Diego Growth Conference on Friday, August 19, 2005, at 10:00 a.m.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Comments on Civil Litigation
Company and Officers to Vigorously Contest Verdict SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Election of Michael T. Borer to Board of Directors
SAN DIEGO, Sept 13, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Officially Opens New Chemistry R&D Facility in Sweden
SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today officially opened its modern
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 2005 UBS Global Life Sciences Conference on September 27, 2005
SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the 2005 UBS Global Life Sciences Conference on Tuesday, September 27, 2005, at 10:00 a.m.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Study Identifies Molecular Properties of ACP-104 That Predict Unique Antipsychotic Activity
ACP-104, Major Metabolite of Clozapine, Partially Activates Dopamine D2 and D3 Receptors SAN DIEGO, Sept. 22 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Earns Milestone on Advancement of Neuropathic Pain Clinical Program
SAN DIEGO, Oct 03, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at BIO InvestorForum 2005 on October 20, 2005
SAN DIEGO, Oct 13, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at BIO InvestorForum 2005 on Thursday, October 20, 2005, at 12:00 p.m.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on November 8, 2005
SAN DIEGO, Nov 01, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that Uli Hacksell, Ph.D., Chief Executive Officer, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Tuesday, November 8, 2005, at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2005 Financial Results on November 10, 2005
ACADIA to Host Conference Call and Webcast on Thursday, November 10, 2005, at 5:00 p.m. Eastern Time SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Initial Results From Ongoing Single-Dose Clinical Trial of ACP-104 in Schizophrenia Patients
SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced initial results from an
Printer Friendly Version
Toggle Summary Acadia Pharmaceuticals Reports Third Quarter 2005 Financial Results
SAN DIEGO, Nov 10, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Results From Phase II Study of ACP-103 in Schizophrenia Patients With Haloperidol-Induced Akathisia
SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported results from a Phase II study
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Discovers Novel Isoform-Selective Retinoic Acid Receptor Agonists
SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced publication of research, in
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of David C. Furlano, Ph.D., as Vice President, Regulatory Affairs
SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, today announced the appointment of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Additional $10 Million Equity Investment by Sepracor
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, today announced that Sepracor Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference 2006 on February 14, 2006
SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Uli Hacksell, Ph.D.,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Advancements in Two Preclinical Programs
SAN DIEGO, Feb 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2005 Results on March 1, 2006
ACADIA to Host Conference Call and Webcast on Wednesday, March 1, 2006, at 5:00 p.m. Eastern Time SAN DIEGO, Feb. 22 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2005
SAN DIEGO, March 1 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, March 2, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease
Conference Call Scheduled for Today, March 23, 2006 at 5:00 p.m. Eastern Time SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today reported results from its Phase II clinical trial of ACP-103 in patients with Parkinson's disease suffering from
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Positive Clinical Trial Results Demonstrating That ACP-103 Increases Slow Wave Sleep
SAN DIEGO, April 19 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today reported top-line results from a proof-of-concept clinical study that assessed the effect of ACP-103 on deep, or slow wave, sleep in healthy older volunteers using polysomnography (PSG).
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Stock Offering
SAN DIEGO, April 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the filing of a preliminary prospectus supplement to its effective shelf registration statement previously filed with the Securities and Exchange Commission
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering
SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the pricing of its public offering of 4,947,229 shares of its common stock. The public offering price of $12.00 per share resulted in gross proceeds of $59.4 million and net proceeds, after
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2006 Financial Results on May 10, 2006
ACADIA to Host Conference Call and Webcast on Wednesday, May 10, 2006, at 5:00 p.m. Eastern Time SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2006 Financial Results
SAN DIEGO, May 10 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Added to NASDAQ Biotech Index
SAN DIEGO, May 15, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Roger G. Mills, M.D., as Executive Vice President, Development
SAN DIEGO, June 5 /PRNewswire-FirstCall/ -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the appointment of Roger G.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Needham's Fifth Annual Biotechnology and Medical Technology Conference
SAN DIEGO--(BUSINESS WIRE)--June 8, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at Needham
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Jefferies Life Sciences Conference on June 27, 2006
SAN DIEGO--(BUSINESS WIRE)--June 20, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Encouraging Results from Initial Clinical Trials with ACP-104 in Patients with Schizophrenia
SAN DIEGO--(BUSINESS WIRE)--July 13, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced results from three initial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2006 Financial Results on August 8, 2006; ACADIA to Host Conference Call and Webcast on Tuesday, August 8, 2006, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Aug. 2, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Aug. 3, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2006 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Sept. 12, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Accelerated Timing of ACP-103 Phase II Trial in Patients with Schizophrenia; Top-Line Results for Complete 400-Patient Study Expected in Q1 2007
SAN DIEGO--(BUSINESS WIRE)--Sept. 25, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on the timing of its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at BIO InvestorForum 2006 on October 18, 2006
SAN DIEGO--(BUSINESS WIRE)--Oct. 11, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at BIO
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Support Launch of New Company Focused on Substance Abuse Therapeutics
Mark R. Brann, Ph.D., to Become CEO of Abbey Pharmaceuticals SAN DIEGO, Oct 23, 2006 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will provide initial seed funding to help establish Abbey Pharmaceuticals, a startup biotechnology company focused on
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2006 Financial Results on November 6, 2006
SAN DIEGO--(BUSINESS WIRE)--Oct. 30, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Nov. 1, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2006 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 6, 2006--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Adds Complementary Intellectual Property for Serotonin Platform
SAN DIEGO, Dec 04, 2006 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has expanded and
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 25th Annual JP Morgan Healthcare Conference on January 11, 2007
SAN DIEGO--(BUSINESS WIRE)--Jan. 3, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the 25th
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 13, 2007
SAN DIEGO--(BUSINESS WIRE)--Feb. 6, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the BIO
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2006 Financial Results on March 6, 2007
ACADIA to Host Conference Call and Webcast on Tuesday, March 6, 2007, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2006
SAN DIEGO--(BUSINESS WIRE)--March 6, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Lehman Brothers 10th Annual Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--March 14, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at Lehman
Printer Friendly Version
Toggle Summary ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial
-- Enhanced Antipsychotic Efficacy -- -- Faster Onset of Action -- -- Less Weight Gain -- -- Conference Call Scheduled for Today, March 19, 2007, at 9:00 a.m. Eastern Time – SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
SAN DIEGO--(BUSINESS WIRE)--March 29, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Stock Offering
SAN DIEGO--(BUSINESS WIRE)--April 2, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) announced today the filing of a preliminary prospectus supplement to its effective shelf registration statement previously filed with the Securities and Exchange Commission relating to a proposed underwritten
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering
SAN DIEGO--(BUSINESS WIRE)--April 4, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the pricing of its public offering of 5,750,000 shares of its common stock. The public offering price of $15.50 per share will result in gross proceeds of $89.1 million and net proceeds, after
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--April 18, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Exercise of Over-Allotment by Underwriters
SAN DIEGO--(BUSINESS WIRE)--April 20, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) announced today that the underwriters have exercised in full their over-allotment option to purchase 862,500 shares of the Company's common stock, in connection with its public offering that priced on April 4,
Printer Friendly Version
Toggle Summary Pimavanserin Approved by USAN as Nonproprietary Name for ACADIA Drug Candidate ACP-103
SAN DIEGO--(BUSINESS WIRE)--April 24, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the United States Adopted
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2007 Financial Results on May 8, 2007
ACADIA to Host Conference Call and Webcast on Tuesday, May 8, 2007, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--May 1, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2007 Financial Results
SAN DIEGO, May 08, 2007 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--May 24, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
SAN DIEGO, Jun 11, 2007 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the initiation of its first
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia
SAN DIEGO--(BUSINESS WIRE)--June 26, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the initiation of a Phase IIb
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Earns Milestone on Advancement of Glaucoma Drug Candidate
SAN DIEGO--(BUSINESS WIRE)--July 16, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Allergan, Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2007 Financial Results on August 6, 2007
ACADIA to Host Conference Call and Webcast on Monday, August 6, 2007, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--July 30, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Canaccord Adams 27th Annual Global Growth Conference
SAN DIEGO--(BUSINESS WIRE)--Aug. 1, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2007 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Aug. 6, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
SAN DIEGO--(BUSINESS WIRE)--Sept. 19, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
SAN DIEGO--(BUSINESS WIRE)--Sept. 25, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been selected to
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at BIO InvestorForum 2007 on October 10, 2007
SAN DIEGO--(BUSINESS WIRE)--Oct. 3, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at BIO
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Oct. 26, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 5, 2007
ACADIA to Host Conference Call and Webcast on Monday, November 5, 2007, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present Preclinical Data on Its Advanced Schizophrenia Programs at the 37th Annual Meeting of the Society for Neuroscience
Data Demonstrate Cognitive Advantages of Co-Therapy with Pimavanserin and Stand-alone Therapy with ACP-104 SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2007 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Webcast Its Analyst and Investor Meeting on December 14, 2007
SAN DIEGO--(BUSINESS WIRE)--Dec. 6, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will host a live webcast
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule
Top-Line Results Expected in Q2 2008 SAN DIEGO--(BUSINESS WIRE)--Dec. 14, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 26th Annual JP Morgan Healthcare Conference on January 7, 2008
SAN DIEGO, Dec 26, 2007 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 12, 2008
SAN DIEGO, Feb 04, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the BIO
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Presentation of Data on Pimavanserin Co-Therapy at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
New Data Demonstrate Less Increase in Serum Glucose Levels With Pimavanserin Co-Therapy SAN DIEGO, Feb 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints John J. Kaiser as Vice President, Strategic Marketing and Commercial Development
SAN DIEGO, Feb 12, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the appointment of John J.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 5, 2008
ACADIA to Host Conference Call and Webcast on Wednesday, March 5, 2008, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2007
SAN DIEGO--(BUSINESS WIRE)--March 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Lehman Brothers 11th Annual Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--March 11, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 8th Annual Fortis Bank Biotechnology Conference
SAN DIEGO, Mar 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--March 31, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present Preclinical Data on ACP-104, ACP-105 and Its Muscarinic Discovery Program at Experimental Biology 2008 Meeting
SAN DIEGO--(BUSINESS WIRE)--April 4, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present Data from Its Phase II Trial with Pimavanserin for Parkinson's Disease Psychosis at the 60th American Academy of Neurology Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--April 16, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the company will present
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 5, 2008
ACADIA to Host Conference Call and Webcast on Monday, May 5, 2008, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--April 28, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--April 30, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Election of Laura A. Brege to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the election of Laura A.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2008 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system (CNS) disorders, today reported its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--May 14, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--June 4, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial
-- Conference Call Scheduled for Today, June 16, 2008, at 8:30 a.m. Eastern Time -- SAN DIEGO--(BUSINESS WIRE)--June 16, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
ACADIA to Host Conference Call and Webcast on Tuesday, August 5, 2008, at 8:30 a.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--July 29, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Second Quarter 2008 Financial Results and Strategic Restructuring
SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Secures Committed Equity Financing Facility
SAN DIEGO, Aug 05, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at The Thomas Weisel Partners Healthcare Conference on September 4, 2008
SAN DIEGO, Aug 28, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Files Registration Statement as Required by Previously Announced Committed Equity Financing Facility
SAN DIEGO--(BUSINESS WIRE)--Sept. 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it filed a registration
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2008
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the JMP Securities
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the following
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2008 Financial Results on November 5, 2008
ACADIA to Host Conference Call and Webcast on Wednesday, November 5, 2008, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
SAN DIEGO--(BUSINESS WIRE)--Nov. 3, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2008 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2008--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at The 20th Annual Piper Jaffray Health Care Conference on December 3, 2008
SAN DIEGO, Nov 25, 2008 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at The
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel ER-beta Agonists for the Treatment of Parkinson’s Disease
SAN DIEGO --(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a grant from The
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009
SAN DIEGO --(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the BIO CEO &
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2008 Financial Results on March 9, 2009
ACADIA to Host Conference Call and Webcast on Monday, March 9, 2009, at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Mar. 2, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference on March 11, 2009
SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2008
SAN DIEGO --(BUSINESS WIRE)--Mar. 9, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals and Meiji Seika Kaisha Form Collaboration to Develop and Commercialize a New Class of Pro-Cognitive Schizophrenia Drugs
Meiji Seika Granted Rights to Develop and Commercialize Products in Asian Territory; ACADIA Retains All Rights in the Rest of the World SAN DIEGO --(BUSINESS WIRE)--Mar. 25, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Meiji Seika Kaisha, Ltd.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America
Conference Call Scheduled for Today, May 4, 2009, at 8:30 a.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--May. 4, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) today announced that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2009 Financial Results on May 11, 2009
ACADIA to Host Conference Call and Webcast on Monday, May 11, 2009, at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--May. 5, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Top-Line Data Expected in the Third Quarter of 2009 SAN DIEGO & TORONTO --(BUSINESS WIRE)--May. 6, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) and Biovail Corporation (NYSE:BVF) (TSX:BVF), today announced the completion of enrollment in the first pivotal Phase III clinical trial of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2009 Financial Results
SAN DIEGO --(BUSINESS WIRE)--May. 11, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Eighth Annual JMP Securities Research Conference on May 19, 2009
SAN DIEGO --(BUSINESS WIRE)--May. 13, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Eighth Annual Needham Life Sciences Conference on June 10, 2009
SAN DIEGO --(BUSINESS WIRE)--Jun. 3, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009
ACADIA to Host Conference Call and Webcast on Wednesday, August 5, 2009, at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 29, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results
SAN DIEGO --(BUSINESS WIRE)--Aug. 5, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
Pimavanserin Misses Primary Endpoint of Antipsychotic Efficacy; Meets Key Secondary Endpoint of Motoric Tolerability Conference Call Scheduled for Today, September 1 , at 8:00 A.M. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Sep. 1, 2009-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Provides Update on Pimavanserin Collaborative Development Program
SAN DIEGO --(BUSINESS WIRE)--Oct. 6, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference on October 6, 2009
SAN DIEGO --(BUSINESS WIRE)--Oct. 6, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the BIOCOM Investor Conference on October 26, 2009
SAN DIEGO --(BUSINESS WIRE)--Oct. 20, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 9, 2009
ACADIA to Host Conference Call and Webcast on Monday, November 9, 2009 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Nov. 2, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2009 Financial Results
SAN DIEGO --(BUSINESS WIRE)--Nov. 9, 2009-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 8, 2010
SAN DIEGO, Feb 01, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 9, 2010
ACADIA to Host Conference Call and Webcast on Tuesday, March 9, 2010, at 5:00 p.m. Eastern Time SAN DIEGO, Mar 02, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2009
SAN DIEGO, Mar 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its financial results for the
Printer Friendly Version
Toggle Summary Dr. Joseph Friedman to Present Data From ACADIA Pharmaceuticals' First Phase III Trial With Pimavanserin for Parkinson's Disease Psychosis at the 62nd American Academy of Neurology Annual Meeting
SAN DIEGO, Apr 14, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that Joseph H.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2010 Financial Results on May 10, 2010
ACADIA to Host Conference Call and Webcast on Monday, May 10, 2010, at 5:00 p.m. Eastern Time SAN DIEGO, May 03, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Ninth Annual JMP Securities Research Conference on May 12, 2010
SAN DIEGO, May 05, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2010 Financial Results
SAN DIEGO, May 10, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals To Present at the Ninth Annual Needham Healthcare Conference on June 9, 2010
SAN DIEGO, Jun 02, 2010 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Initiation of New Phase III Trial with Pimavanserin for Parkinson's Disease Psychosis
SAN DIEGO, Jul 29, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 9, 2010
ACADIA to Host Conference Call and Webcast on Monday, August 9, 2010, at 5:00 p.m. Eastern Time SAN DIEGO, Aug 02, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2010 Financial Results
SAN DIEGO, Aug 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO, Sep 07, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010
SAN DIEGO, Sep 22, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Enters Agreement with Biovail to Conclude Collaboration and Regain North American Rights to Pimavanserin
ACADIA Now Holds Worldwide Rights; Receives $8.75 Million Payment to Continue Ongoing Phase III Trials in Parkinson's Disease Psychosis ACADIA Conference Call Scheduled for Today, October 28, at 9:00 A.M. Eastern Time SAN DIEGO, Oct 28, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 9, 2010
ACADIA to Host Conference Call and Webcast on Tuesday, November 9, 2010, at 5:00 p.m. Eastern Time SAN DIEGO, Nov 02, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Awarded Grant from The Michael J. Fox Foundation for the Development of Novel Nurr1-RXR Agonists to Treat Parkinson's Disease
SAN DIEGO, Nov 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2010 Financial Results
SAN DIEGO, Nov 09, 2010 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces $15 Million Private Placement
--Proceeds to Support Advancement of Pimavanserin Phase III Program-- SAN DIEGO, Jan 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Thirteenth Annual BIO CEO & Investor Conference on February 15, 2011
SAN DIEGO, Feb 08, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Financial Results on March 10, 2011
ACADIA to Host Conference Call and Webcast on Thursday, March 10, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, Mar 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
SAN DIEGO, Mar 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced its financial results for the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Tenth Annual Needham Healthcare Conference on April 5, 2011
SAN DIEGO, Mar 29, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
SAN DIEGO, Apr 01, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 10, 2011
ACADIA to Host Conference Call and Webcast on Tuesday, May 10, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, May 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Tenth Annual JMP Securities Research Conference on May 11, 2011
SAN DIEGO, May 04, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2011 Financial Results
SAN DIEGO, May 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Awarded Grant from National Institutes of Health for the Development of Novel ER-beta Agonists
SAN DIEGO, May 17, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 10, 2011
ACADIA to Host Conference Call and Webcast on Wednesday, August 10, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, Aug 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2011 Financial Results
SAN DIEGO, Aug 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
SAN DIEGO, Sep 06, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference on September 28, 2011
SAN DIEGO, Sep 21, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 9, 2011
ACADIA to Host Conference Call and Webcast on Wednesday, November 9, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, Nov 02, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Advances AM-831 to Phase I Clinical Development in Collaboration with Meiji Seika Pharma
--FDA Accepts Investigational New Drug Application for AM-831-- SAN DIEGO, Nov 07, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2011 Financial Results
SAN DIEGO, Nov 09, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011
SAN DIEGO --(BUSINESS WIRE)--Dec. 7, 2011-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Election of Bill Wells to Its Board of Directors
SAN DIEGO --(BUSINESS WIRE)--Jan. 30, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the election of William
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012
SAN DIEGO --(BUSINESS WIRE)--Feb. 6, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2011 Financial Results on March 6, 2012
ACADIA to Host Conference Call and Webcast on Tuesday, March 6, 2012 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 28, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Feb. 29, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
SAN DIEGO --(BUSINESS WIRE)--Mar. 5, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has extended its drug discovery
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2011
SAN DIEGO --(BUSINESS WIRE)--Mar. 6, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson’s Disease
SAN DIEGO --(BUSINESS WIRE)--Mar. 27, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has been awarded a new grant
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference on April 3, 2012
SAN DIEGO --(BUSINESS WIRE)--Mar. 28, 2012-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 11 th
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 19th Annual Future Leaders in the Biotech Industry Conference on April 20, 2012
SAN DIEGO, Apr 13, 2012 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 19 th Annual
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012
ACADIA to Host Conference Call and Webcast on Tuesday, May 8, 2012 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--May 1, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2012 Financial Results
SAN DIEGO--(BUSINESS WIRE)--May 8, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Webcast Educational Program on Parkinson’s Disease Psychosis on May 22, 2012
SAN DIEGO--(BUSINESS WIRE)--May 15, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will host a live webcast of its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference on July 13, 2012
SAN DIEGO --(BUSINESS WIRE)--Jul. 9, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 7 th Annual
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin in Preclinical Model of Alzheimer’s Disease Psychosis
SAN DIEGO --(BUSINESS WIRE)--Jul. 9, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 8, 2012
ACADIA to Host Conference Call and Webcast on Wednesday, August 8, 2012 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Aug. 1, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2012 Financial Results
SAN DIEGO --(BUSINESS WIRE)--Aug. 8, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Aug. 29, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis
Top-Line Data Expected in November 2012 SAN DIEGO --(BUSINESS WIRE)--Sep. 5, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 5, 2012
ACADIA to Host Conference Call and Webcast on Monday, November 5, 2012 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Oct. 29, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2012 Financial Results
SAN DIEGO --(BUSINESS WIRE)--Nov. 5, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27, 2012 at 8:00 AM EST to Present Top-Line Results from Its Pivotal Phase III Pimavanserin Parkinson’s Disease Psychosis Trial
SAN DIEGO --(BUSINESS WIRE)--Nov. 26, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will host a conference call and
Printer Friendly Version
Toggle Summary ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson’s Disease Psychosis Trial
Pimavanserin Demonstrates Highly Significant Antipsychotic Efficacy and Maintenance of Motor Control in Parkinson’s Patients Significant Improvements Also Observed in All Secondary and Exploratory Measures Conference Call and Webcast to Be Held Today, November 27, 2012 , at 8:00 am Eastern Time SAN
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces $86 Million Equity Financing
--Proceeds to Support Completion of Pimavanserin Phase III Program-- SAN DIEGO --(BUSINESS WIRE)--Dec. 12, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference Today, December 12, 2012
SAN DIEGO --(BUSINESS WIRE)--Dec. 12, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the Oppenheimer 23 rd
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Receive Funding from Fast Forward and EMD Serono for Multiple Sclerosis Program
Award Will Advance ACADIA’s Selective ER-Beta Agonist as a Potential New Neuroprotective MS Therapy through Collaborative Research with UCLA SAN DIEGO --(BUSINESS WIRE)--Dec. 20, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Election of Stephen R. Biggar to Its Board of Directors
SAN DIEGO --(BUSINESS WIRE)--Jan. 22, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the election of Stephen R.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference on February 12, 2013
SAN DIEGO --(BUSINESS WIRE)--Feb. 5, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the 15 th Annual BIO
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference on March 4, 2013
SAN DIEGO --(BUSINESS WIRE)--Feb. 25, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Cowen and
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013
ACADIA to Host Conference Call and Webcast on Tuesday, March 12, 2013 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Mar. 5, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
SAN DIEGO --(BUSINESS WIRE)--Mar. 12, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its financial results for the fourth
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 25th Annual ROTH Conference on March 19, 2013
SAN DIEGO--(BUSINESS WIRE)--Mar. 13, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 25 th
Printer Friendly Version
Toggle Summary ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
SAN DIEGO --(BUSINESS WIRE)--Mar. 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that Jeffrey Cummings , M.D., Sc.D.,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Expedited Path to NDA Filing for Pimavanserin Following Meeting with FDA
Single Pivotal Phase III -020 Study and Other Supportive Data Sufficient for Future NDA Filing for the Treatment of Parkinson’s Disease Psychosis Conference Call and Webcast to Be Held Today, April 11, 2013 , at 8:00 am Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 12th Annual Needham Healthcare Conference on April 30, 2013
SAN DIEGO --(BUSINESS WIRE)--Apr. 25, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 12 th
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 7, 2013
ACADIA to Host Conference Call and Webcast on Tuesday, May 7, 2013 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 30, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2013 Financial Results
SAN DIEGO --(BUSINESS WIRE)--May 7, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--May 14, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--May 15, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $12.50 per share. The gross proceeds from this offering to ACADIA are
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index
SAN DIEGO --(BUSINESS WIRE)--May 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it has been selected for addition to the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--May 20, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the completion of an underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the full exercise of an option to purchase additional shares
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 5, 2013
SAN DIEGO --(BUSINESS WIRE)--May 29, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical Development
SAN DIEGO --(BUSINESS WIRE)--Jun. 3, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that Allergan, Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Multiple Presentations of Data from Phase III Pimavanserin Program at the 17th International Congress of Parkinson’s Disease and Movement Disorders
SAN DIEGO --(BUSINESS WIRE)--Jun. 18, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, presented data today from its Phase III program with
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Added to Russell 2000 Index
SAN DIEGO --(BUSINESS WIRE)--Jul. 1, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has been added to the Russell
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 8th Annual JMP Securities Healthcare Conference on July 9, 2013
SAN DIEGO --(BUSINESS WIRE)--Jul. 2, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 8 th Annual
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2013 Financial Results on August 6, 2013
ACADIA to Host Conference Call and Webcast on Tuesday, August 6, 2013 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 30, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2013 Financial Results
SAN DIEGO --(BUSINESS WIRE)--Aug. 6, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Terrence Moore as Executive Vice President and Chief Commercial Officer
SAN DIEGO --(BUSINESS WIRE)--Aug. 19, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Terrence Moore as
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Sep. 3, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 6, 2013
ACADIA to Host Conference Call and Webcast on Wednesday, November 6, 2013 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Oct. 30, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Publication in The Lancet of Pivotal Phase III Parkinson’s Disease Psychosis Trial with Pimavanserin
SAN DIEGO --(BUSINESS WIRE)--Oct. 31, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the publication of data from its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2013 Financial Results
SAN DIEGO --(BUSINESS WIRE)--Nov. 6, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Initiation of Phase II Trial with Pimavanserin for Alzheimer’s Disease Psychosis
SAN DIEGO --(BUSINESS WIRE)--Nov. 14, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Nov. 26, 2013-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
ACADIA to Host Conference Call and Webcast on Thursday, February 27, 2014 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 20, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2013
SAN DIEGO --(BUSINESS WIRE)--Feb. 27, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Mar. 3, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28.50 per share. The gross proceeds from this offering to ACADIA are
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Mar. 5, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014
SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 6, 2014
ACADIA to Host Conference Call and Webcast on Tuesday, May 6, 2014 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 29, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--May 1, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2014 Financial Results
SAN DIEGO --(BUSINESS WIRE)--May 6, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference on June 2, 2014
SAN DIEGO --(BUSINESS WIRE)--May 27, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference on June 24, 2014
SAN DIEGO --(BUSINESS WIRE)--Jun. 17, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer
SAN DIEGO --(BUSINESS WIRE)--Jul. 15, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, announced the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014
ACADIA to Host Conference Call and Webcast on Tuesday, August 5, 2014 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 29, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results
SAN DIEGO --(BUSINESS WIRE)--Aug. 5, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin
SAN DIEGO --(BUSINESS WIRE)--Aug. 28, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis
FDA Decision Highlights Significant Unmet Need in the Treatment of Parkinson’s Disease Psychosis SAN DIEGO --(BUSINESS WIRE)--Sep. 2, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2014 Financial Results on November 10, 2014
ACADIA to Host Conference Call and Webcast on Monday, November 10, 2014 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Nov. 3, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results and Updates Timing of NUPLAZID™ NDA Submission
SAN DIEGO --(BUSINESS WIRE)--Nov. 10, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference on November 20, 2014
SAN DIEGO --(BUSINESS WIRE)--Nov. 13, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Nov. 25, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders
Data Demonstrate a Decreased Burden Among Caregivers of Patients with Parkinson’s Disease Psychosis Treated with NUPLAZID™ (Pimavanserin ) SAN DIEGO --(BUSINESS WIRE)--Dec. 8, 2014-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the presentation of caregiver burden data from its Phase
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015
SAN DIEGO --(BUSINESS WIRE)--Jan. 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 33rd Annual
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015
ACADIA to Host Conference Call and Webcast on Thursday, February 26, 2015 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 19, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO --(BUSINESS WIRE)--Feb. 24, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the following
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014
SAN DIEGO --(BUSINESS WIRE)--Feb. 26, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZID™ NDA Submission
Conference Call Scheduled for Today, March 11 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer
Steve Davis Appointed Interim Chief Executive Officer SAN DIEGO --(BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors
SAN DIEGO --(BUSINESS WIRE)--Mar. 26, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference on April 14, 2015
SAN DIEGO --(BUSINESS WIRE)--Apr. 7, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the 14 th
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015
ACADIA to Host Conference Call and Webcast on Thursday, May 7, 2015 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015
SAN DIEGO --(BUSINESS WIRE)--May 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Bank of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results
SAN DIEGO --(BUSINESS WIRE)--May 7, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015
SAN DIEGO --(BUSINESS WIRE)--May 26, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the Jefferies
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
Data from Integrated Analysis of Two Phase III Studies Show Robust and Consistent Efficacy of NUPLAZID Across a Wide Array of Study Measures Data from Two Open-Label Studies Demonstrate Attractive Safety and Tolerability Profile and Potential for Long-Term Effectiveness of NUPLAZID in Parkinson’s
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015
SAN DIEGO --(BUSINESS WIRE)--Jun. 17, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will present at the JMP
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015
ACADIA to Host Conference Call and Webcast on Thursday, August 6, 2015 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development
SAN DIEGO --(BUSINESS WIRE)--Aug. 5, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association
SAN DIEGO --(BUSINESS WIRE)--Aug. 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results
SAN DIEGO --(BUSINESS WIRE)--Aug. 6, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
SAN DIEGO --(BUSINESS WIRE)--Sep. 3, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it has submitted a New
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer
SAN DIEGO --(BUSINESS WIRE)--Sep. 3, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that its Board of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
SAN DIEGO --(BUSINESS WIRE)--Sep. 22, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter Financial Results on November 5, 2015
ACADIA to Host Conference Call and Webcast on Thursday, November 5, 2015 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Oct. 29, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis
PDUFA Date Set for May 1, 2016 SAN DIEGO --(BUSINESS WIRE)--Nov. 2, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference on November 10, 2015
SAN DIEGO --(BUSINESS WIRE)--Nov. 4, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results
SAN DIEGO --(BUSINESS WIRE)--Nov. 5, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors
SAN DIEGO --(BUSINESS WIRE)--Nov. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Edmund P.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development
SAN DIEGO --(BUSINESS WIRE)--Nov. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors
SAN DIEGO --(BUSINESS WIRE)--Dec. 15, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced Julian C.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Jan. 5, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it intends to offer
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Jan. 6, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the pricing of an
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016
SAN DIEGO --(BUSINESS WIRE)--Jan. 7, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors
SAN DIEGO --(BUSINESS WIRE)--Jan. 11, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced Jim Daly has joined
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer
SAN DIEGO --(BUSINESS WIRE)--Jan. 25, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID™ (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis
Advisory Committee Meeting Scheduled for March 29, 2016 SAN DIEGO --(BUSINESS WIRE)--Jan. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016
SAN DIEGO --(BUSINESS WIRE)--Feb. 3, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016
ACADIA to Host Conference Call and Webcast on Monday, February 29, 2016 , at 8:00 a.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
SAN DIEGO --(BUSINESS WIRE)--Feb. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016
SAN DIEGO --(BUSINESS WIRE)--Mar. 1, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Stock Trading Halted Today
FDA Advisory Committee to Review NUPLAZID™ (Pimavanserin) New Drug Application for the Treatment of Parkinson’s Disease Psychosis SAN DIEGO --(BUSINESS WIRE)--Mar. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of
Printer Friendly Version
Toggle Summary FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
SAN DIEGO --(BUSINESS WIRE)--Mar. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that the U.S.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
SAN DIEGO --(BUSINESS WIRE)--Apr. 6, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
U.S. Commercial Launch Planned for June 2016 An Estimated 40 Percent of Parkinson’s Disease Patients Have Psychosis Conference Call Scheduled on Monday, May 2 at 8:30 a.m. ET SAN DIEGO --(BUSINESS WIRE)--Apr. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016
ACADIA to Host Conference Call and Webcast on Thursday, May 5, 2016 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--May 2, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016
SAN DIEGO --(BUSINESS WIRE)--May 4, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
SAN DIEGO --(BUSINESS WIRE)--May 5, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its unaudited financial
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
NUPLAZID is the First and Only FDA-Approved Drug for this Indication An Estimated 40 Percent of Parkinson’s Disease Patients Have Psychosis SAN DIEGO --(BUSINESS WIRE)--May 31, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016
SAN DIEGO --(BUSINESS WIRE)--Jun. 1, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016
SAN DIEGO --(BUSINESS WIRE)--Jun. 16, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index
SAN DIEGO --(BUSINESS WIRE)--Jun. 27, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it has been added
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016
ACADIA to Host Conference Call and Webcast on Thursday, August 4, 2016 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 29, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results
Quarter highlighted by approval and launch of NUPLAZID™ (pimavanserin) in the United States , the first and only FDA -approved drug for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis SAN DIEGO --(BUSINESS WIRE)--Aug. 4, 2016-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Aug. 8, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it intends to offer
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Aug. 9, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the pricing of an
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO --(BUSINESS WIRE)--Aug. 23, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that the underwriters for
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
SAN DIEGO --(BUSINESS WIRE)--Aug. 24, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders, today announced the appointment
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2016
SAN DIEGO --(BUSINESS WIRE)--Sep. 6, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Sponsors National Parkinson Foundation’s Caregiver Summit
ACADIA to Host Booths and Present Posters at the 4 th World Parkinson Congress SAN DIEGO --(BUSINESS WIRE)--Sep. 19, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
SAN DIEGO --(BUSINESS WIRE)--Sep. 20, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Receives California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™
SAN DIEGO --(BUSINESS WIRE)--Oct. 11, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders, has been awarded the California
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation
SAN DIEGO --(BUSINESS WIRE)--Oct. 31, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of SERENE, a Phase II study with pimavanserin
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 7, 2016
ACADIA to Host Conference Call and Webcast on Monday, November 7, 2016 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Nov. 1, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia
SAN DIEGO --(BUSINESS WIRE)--Nov. 3, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of ENHANCE-1, a Phase III study to evaluate
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results
NUPLAZID ® Net Product Sales Grew to $5.3 Million in the First Full Quarter of Commercialization Expanding Pimavanserin Clinical Program With Initiation of Studies for Alzheimer’s Disease Agitation and Adjunctive Treatment of Schizophrenia SAN DIEGO --(BUSINESS WIRE)--Nov.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia
SAN DIEGO --(BUSINESS WIRE)--Nov. 15, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system disorders, today announced the initiation of ADVANCE, a Phase II study to evaluate
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder
SAN DIEGO --(BUSINESS WIRE)--Dec. 1, 2016-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of CLARITY, a Phase II study to evaluate
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer’s Disease Psychosis
Data Support Moving Forward With Further Development in Alzheimer’s Disease Psychosis Conference Call and Webcast to Be Held Today, December 20, 2016 , at 8:30 a.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Dec. 20, 2016-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017
SAN DIEGO --(BUSINESS WIRE)--Jan. 3, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 28, 2017
ACADIA to Host Conference Call and Webcast on Tuesday, February 28, 2017 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 21, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017
SAN DIEGO --(BUSINESS WIRE)--Feb. 27, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
NUPLAZID ® Net Product Sales Grew to $12.0 Million in Fourth Quarter 2016 Executing on Broad Clinical Development Program in Alzheimer’s Disease Psychosis, Alzheimer’s Disease Agitation, Schizophrenia Inadequate Response, Negative Symptoms of Schizophrenia, and Major Depressive Disorder SAN DIEGO
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at Needham & Company’s 16th Annual Healthcare Conference on April 5, 2017
SAN DIEGO --(BUSINESS WIRE)--Mar. 29, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer
Terrence O. Moore Retires as Chief Commercial Officer SAN DIEGO --(BUSINESS WIRE)--Mar. 30, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017
ACADIA to Host Conference Call and Webcast on Tuesday, May 9, 2017 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--May 2, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017
SAN DIEGO --(BUSINESS WIRE)--May 8, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results
SAN DIEGO --(BUSINESS WIRE)--May 9, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Named to Forbes Magazine’s List of World’s Most Innovative Growth Companies
SAN DIEGO --(BUSINESS WIRE)--Jul. 25, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has been ranked 11 th on Forbes Magazine’s 2017 list of the World’s Most Innovative Growth Companies. ACADIA is a biopharmaceutical company dedicated to developing and delivering
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017
ACADIA to Host Conference Call and Webcast on Tuesday, August 8, 2017 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Aug. 1, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results
Second Quarter Net Sales Grew to $30.5 Million Including $3.6 Million From Transition to Sell-In Method of Accounting SAN DIEGO --(BUSINESS WIRE)--Aug. 8, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
SAN DIEGO --(BUSINESS WIRE)--Sep. 19, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase III Study of Pimavanserin in Dementia-Related Psychosis
Dementia-Related Psychosis Includes Psychosis in Patients with Alzheimer’s Disease, Dementia with Lewy Bodies, Parkinson’s Disease Dementia, Vascular Dementia, and Frontotemporal Dementia FDA Grants Breakthrough Therapy Designation to Pimavanserin for Dementia-Related Psychosis Conference Call to
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
ACADIA to Host Conference Call and Webcast on Tuesday, November 7, 2017 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Oct. 31, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Presents Data from the Phase II Study of Pimavanserin in Alzheimer’s Disease Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2017 Meeting
Data Confirmed Significant Improvement in Psychosis in Patients with Alzheimer’s Disease with Substantively Greater Benefit in Patients with More Severe Psychotic Symptoms SAN DIEGO --(BUSINESS WIRE)--Nov. 3, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results
– Third Quarter Net Sales Grew to $35.6 Million – Company Raises Annual 2017 Net Sales Guidance to Between $124 Million and $127 Million SAN DIEGO --(BUSINESS WIRE)--Nov. 7, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
SAN DIEGO --(BUSINESS WIRE)--Nov. 21, 2017-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Damien McDevitt, Ph.D., as Senior Vice President, Corporate Development
SAN DIEGO --(BUSINESS WIRE)--Dec. 13, 2017-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Damien
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018
SAN DIEGO --(BUSINESS WIRE)--Jan. 2, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
ACADIA to Host Conference Call and Webcast on Tuesday, February 27, 2018 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 20, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
-Fourth Quarter and Full Year 2017 Net Sales Grew to $43.6 Million and $124.9 Million , Respectively SAN DIEGO --(BUSINESS WIRE)--Feb. 27, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
SAN DIEGO --(BUSINESS WIRE)--Mar. 6, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
SAN DIEGO --(BUSINESS WIRE)--Mar. 20, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
Results underscore need for greater awareness of non-movement symptoms this Parkinson’s Disease Awareness Month TUCSON, Ariz. & SAN DIEGO --(BUSINESS WIRE)--Apr. 23, 2018-- As part of Parkinson’s Disease Awareness Month, the Parkinson & Movement Disorder Alliance (PMDAlliance) and ACADIA
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
- Concurrently, the Company Has Issued a Press Release Announcing the Presentation of Clinical Experience Data for NUPLAZID at the American Academy of Neurology (AAN) Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2018-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
Two Independent Data Sets Confirm NUPLAZID Is Well-Tolerated and Efficacious in Treating Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis SAN DIEGO --(BUSINESS WIRE)--Apr. 27, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
ACADIA to Host Conference Call and Webcast on Friday, May 4, 2018 , at 8:30 a.m. Eastern Time SAN DIEGO, Calif. --(BUSINESS WIRE)--May 1, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
SAN DIEGO --(BUSINESS WIRE)--May 2, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Elena Ridloff ,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
– Strong Performance for NUPLAZID ® in First Quarter 2018 – First Quarter Net Sales Grew to $48.9 Million , Representing a 12% Sequential Increase Over 4Q17 and 220% Increase Over 1Q17 – ACADIA Reiterates 2018 Net Sales Guidance of $255 Million to $270 Million SAN DIEGO --(BUSINESS WIRE)--May 4,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
SAN DIEGO --(BUSINESS WIRE)--May 8, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018
SAN DIEGO --(BUSINESS WIRE)--Jun. 6, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018
SAN DIEGO --(BUSINESS WIRE)--Jun. 13, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
– New Dosing Formulation and Strength Address Needs in Treating Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis SAN DIEGO --(BUSINESS WIRE)--Jun. 29, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
ACADIA to Host Conference Call and Webcast on Wednesday, August 8, 2018 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 30, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
- ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019 -Neuren retains all rights to trofinetide outside of North America -Neuren to receive US $10 million upfront plus potential
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
– Second Quarter Net Sales Grew to $57.1 Million , Representing a 17% Sequential Increase Over 1Q18 and 87% Increase Over 2Q17 – Announced FDA Approval of New Dosing Formulation and Strength of NUPLAZID ® (Pimavanserin) – Expanded ACADIA’s Pipeline in Central Nervous System Disorders with Exclusive
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis
SAN DIEGO --(BUSINESS WIRE)--Sep. 10, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced today publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and efficacy of pimavanserin for the treatment of psychosis in
Printer Friendly Version
Toggle Summary FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
- FDA analysis finds no new or unexpected safety risks associated with NUPLAZID - Patients taking NUPLAZID for Parkinson’s disease psychosis should continue to use it as prescribed by their health care provider - FDA also reminds health care providers that no other antipsychotic medication is
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
SAN DIEGO --(BUSINESS WIRE)--Sep. 25, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
- Robert Kaper , M.D., named Senior Vice President, Global Head of Medical Affairs - Eliseo Salinas , M.D., M.Sc., named Senior Vice President, Chief Scientific Officer and Head of External Innovation SAN DIEGO --(BUSINESS WIRE)--Sep. 26, 2018-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
ACADIA to Host Conference Call and Webcast on Tuesday, November 6, 2018 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Oct. 23, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Executive Leadership Change
SAN DIEGO --(BUSINESS WIRE)--Oct. 29, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that Todd S. Young, Executive Vice President and Chief Financial Officer, will be leaving the organization effective October 31, 2018 to join another healthcare company.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
- Pimavanserin met primary endpoint with statistically significant overall improvement in HAMD-17 total score compared to placebo (p=0.039) - Pimavanserin met key secondary endpoint with statistically significant overall improvement in Sheehan Disability Scale compared to placebo (p=0.004) -
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
-Third Quarter Net Sales Grew to $58.3 Million -Recently Announced Positive Top-line Results from the Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment for Major Depressive Disorder -FDA Issued Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID ® for Patients with
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Nov. 26, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Nov. 27, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO --(BUSINESS WIRE)--Nov. 30, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
SAN DIEGO --(BUSINESS WIRE)--Dec. 20, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 26, 2019
ACADIA to Host Conference Call and Webcast on Tuesday, February 26, 2019 , at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Feb. 12, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
SAN DIEGO --(BUSINESS WIRE)--Feb. 21, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
- Fourth Quarter 2018 Net Sales Grew to $59.6 Million , a 37% Increase Over 4Q17 - Full Year 2018 Net Sales Grew to $223.8 Million , a 79% Increase Over Full Year 2017 - Late Stage Pipeline Progressing with Five Clinical Programs Ongoing or Commencing in 2019 - 2019 Guidance: Net Sales $275 Million
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference on March 11, 2019
SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the American Academy of Neurology
-- Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome -- Trofinetide for Rett Syndrome has Fast Track Status and Orphan Drug Designation in the U.S. and Orphan Drug Designation in Europe SAN DIEGO & CINCINNATI & MELBOURNE, Australia --(BUSINESS
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Promotion of Elena Ridloff, CFA to Executive Vice President, Chief Financial Officer
SAN DIEGO --(BUSINESS WIRE)--Apr. 1, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the promotion of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference on April 9, 2019
SAN DIEGO --(BUSINESS WIRE)--Apr. 2, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Supports Parkinson’s Disease Awareness Month and World Parkinson’s Day with Local Educational Initiatives and Community Events Across the Country
SAN DIEGO --(BUSINESS WIRE)--Apr. 11, 2019-- ACADIA Pharmaceuticals Inc . (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced support of several
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
ACADIA to Host Conference Call and Webcast on Wednesday, May 1, 2019 , at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 17, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program with Pimavanserin as Adjunctive Treatment for Major Depressive Disorder
SAN DIEGO --(BUSINESS WIRE)--Apr. 25, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results
- 1Q19 Net Sales Grew to $63.0 Million , a 29% Increase Over 1Q18 - Updated 2019 Net Sales Guidance to $280 Million to $300 Million - Completed Enrollment in Two Late-Stage Adjunctive Schizophrenia Studies with Pimavanserin SAN DIEGO --(BUSINESS WIRE)--May 1, 2019-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
SAN DIEGO --(BUSINESS WIRE)--May 7, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting
SAN DIEGO --(BUSINESS WIRE)--May 18, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
SAN DIEGO --(BUSINESS WIRE)--Jun. 4, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary New National Event Series "Parkinson's IQ + You" Launches to Educate and Empower Parkinson's Disease Patients and Care Partners
- "Parkinson's IQ + You" events are designed to empower people with Parkinson's and care partners to manage the disease, learn about research participation and connect with local resources - This series of events is presented by The Michael J. Fox Foundation and funded by ACADIA Pharmaceuticals,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
ACADIA to Host Conference Call and Webcast on Wednesday, July 31, 2019 , at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Jul. 17, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
- Pimavanserin did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement of psychotic symptoms (p=0.0940) - Significant improvements observed on secondary endpoint of PANSS negative symptoms scale sub-score (unadjusted p=0.0474) - Conference call
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
- 2Q19 Net Sales Grew to $83.2 Million , a 46% Increase Over 2Q18 - 2019 Net Sales Guidance Increased to $320 Million to $330 Million SAN DIEGO --(BUSINESS WIRE)--Jul. 31, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019
SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
- Pimavanserin achieved robust statistical superiority over placebo in time to relapse of dementia-related psychosis at planned interim efficacy analysis - Pimavanserin has the potential to be the first FDA -approved drug for the treatment of dementia-related psychosis - Approximately 1.2 million
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Sep. 17, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Prices Public Offering of Common Stock
SAN DIEGO --(BUSINESS WIRE)--Sep. 17, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings
— New data presented at the International Congress of Parkinson’s Disease and Movement Disorders will highlight treatment benefit of pimavanserin in patients with comorbid Parkinson’s disease and depression — New data presented at the Psych Congress will highlight improvement on sexual functioning
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN DIEGO --(BUSINESS WIRE)--Sep. 20, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson’s Disease and Movement Disorders
- Pimavanserin as monotherapy or adjunct to SSRI/SNRI therapies significantly improved depression symptoms for Parkinson’s patients     SAN DIEGO --(BUSINESS WIRE)--Sep. 23, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive results from an 8-week, open-label, single-arm
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder
- Pimavanserin as an adjunctive treatment for patients with MDD showed significant overall improvement in HAMD-17 total score compared to placebo   - Phase 3 CLARITY program initiated in April 2019     SAN DIEGO --(BUSINESS WIRE)--Sep. 24, 2019-- ACADIA Pharmaceuticals Inc.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
  SAN DIEGO --(BUSINESS WIRE)--Sep. 25, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer’s Disease (CTAD) 2019 Meeting
  SAN DIEGO --(BUSINESS WIRE)--Oct. 3, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral communication at the upcoming 12 th
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress
  — Pimavanserin as adjunctive treatment to SSRI/SNRI therapies significantly improved sexual dysfunction symptoms compared to placebo in MDD patients     SAN DIEGO --(BUSINESS WIRE)--Oct. 7, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that based on secondary analyses from its
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Announce Third Quarter 2019 Financial Results on October 30, 2019
ACADIA to Host Conference Call and Webcast on Wednesday, October 30, 2019 , at 4:30 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Oct. 16, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
- 3Q19 Net Sales Grew to $94.6 Million , a 62% Increase Over 3Q18 - 2019 Net Sales Guidance Increased to $330 to $340 Million - Initiated Phase 3 LAVENDER Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder SAN DIEGO --(BUSINESS WIRE)--Oct.
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder
SAN DIEGO --(BUSINESS WIRE)--Oct. 30, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it has
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer
SAN DIEGO --(BUSINESS WIRE)--Nov. 4, 2019-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the appointment of Ponni Subbiah , M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer. Dr. Subbiah will report to Serge Stankovic , M.D., M.S.P.H.,
Printer Friendly Version
Toggle Summary ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019
SAN DIEGO --(BUSINESS WIRE)--Nov. 11, 2019-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a treatment for dementia-related
Printer Friendly Version